Successful treatment of c-kit-positive metastatic Adenoid Cystic Carcinoma (ACC) with a combination of curcumin plus imatinib: A case report

dc.authorid0000-0003-4568-4234
dc.contributor.authorDemiray, Mutlu
dc.contributor.authorŞahinbaş, Hüseyin
dc.contributor.authorAtahan, Şafak
dc.contributor.authorDemiray, Hülya
dc.contributor.authorSelçuk, D.
dc.contributor.authorYıldırım, İlknur
dc.contributor.authorAtayoğlu, Ali Timuçin
dc.date.accessioned10.07.201910:49:13
dc.date.accessioned2019-07-10T19:51:32Z
dc.date.available10.07.201910:49:13
dc.date.available2019-07-10T19:51:32Z
dc.date.issued2016
dc.departmentİstanbul Medipol Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Aile Hekimliği Ana Bilim Dalı
dc.descriptionWOS: 000382408400016
dc.descriptionPubMed ID: 27515884
dc.description.abstractAdenoid cystic carcinoma (ACC) is an aggressive malignant neoplasm of the secretory glands. Conventional chemotherapy has poor effectiveness against metastatic ACC. Thus, a novel effective therapy is needed against metastatic ACC. A majority of ACCs (up to 94%) express c-kit. Imatinib is monoclonal antibody with specific activity against c-kit but has not been found to be effective in treating patients with ACC in which c-kit is overexpressed and activated. The NF-kappa B and mTOR pathways have been shown that ubiquitously and concurrently activated, indicating that the inhibition of these pathways may represent a novel treatment approach for patients with ACC. Curcumin has been shown to inhibit NF-kappa B and NF-kappa B-related pathways. 43-year-old patient was diagnosed ACC from submandibular salivary gland. After complete resection of tumor adjuvant radiotherapy was initiated. Seven years later multiple lung metastases were detected and ACC was confirmed by re-biopsy. First-line chemotherapy failed. NF-kappa B and c-kit were over expressed in the metastatic specimens. Therefore, we treated the patient with metastatic chemoresistant ACC with imatinib 400 mg/day and intravenous curcumin 225 mg/m(2) twice a week plus oral bioavailable curcumin Arantal((R)) 2 x 84 mg/day. At 24 months, we observed near complete anatomic and complete metabolic response. To our knowledge, this is the first report of a patient with a c-kit-positive ACC that is successfully treated with the combination of imatinib and curcumin in an integrative approach.
dc.identifier.citationDemiray, M., Şahinbaş, H., Atahan, S., Demiray, H., Selçuk, D.,Yıldırım, I. ve Atayoğlu, A. T. (2016). Successful treatment of c-kit-positive metastatic Adenoid Cystic Carcinoma (ACC) with a combination of curcumin plus imatinib: A case report. Complementary Therapies in Medicine, 27, 108-113. http://dx.doi.org/10.1016/j.ctim.2016.06.009
dc.identifier.doi10.1016/j.ctim.2016.06.009
dc.identifier.endpage113
dc.identifier.issn0965-2299
dc.identifier.issn1873-6963
dc.identifier.scopusqualityQ1
dc.identifier.startpage108
dc.identifier.urihttps://hdl.handle.net/20.500.12511/2234
dc.identifier.urihttp://dx.doi.org/10.1016/j.ctim.2016.06.009
dc.identifier.volume27
dc.identifier.wosqualityQ2
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherChurchill Livingstone
dc.relation.ispartofComplementary Therapies in Medicineen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International*
dc.rightshttps://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectAdenoid Cystic Carcinoma
dc.subjectImatinib
dc.subjectCurcumin
dc.subjectIntegrative Medicine
dc.subjectArantal
dc.titleSuccessful treatment of c-kit-positive metastatic Adenoid Cystic Carcinoma (ACC) with a combination of curcumin plus imatinib: A case report
dc.typeArticle

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Yükleniyor...
Küçük Resim
İsim:
Atayoglu, Ali Timucin.pdf
Boyut:
2.38 MB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text